专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP1984010A4 METHODS USING HYDRALAZINE COMPOUNDS AND ISOSORBIDE DINITRATE OR ISOSORBIDE MONONITRATE 审中-公开
标题翻译：使用方法和HYDRALAZINVERBINDUNGEN消心痛或硝酸异山梨醇酯的
公开(公告)号：EP1984010A4
公开(公告)日：2010-09-08
申请号：EP07750648
申请日：2007-02-12
申请人： NITROMED INC
发明人： LOBERG MICHAEL D
IPC分类号： A61K38/00 , A61K31/15 , A61K31/34 , A61K31/50 , A61K31/502 , A61K31/5025 , A61K45/06 , A61P9/04 , A61P13/12
CPC分类号： A61K45/06 , A61K31/15 , A61K31/34 , A61K31/50 , A61K31/502 , A61K31/5025 , A61K2300/00

2. 发明公开

EP1670459A4 NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE 审中-公开
标题翻译： NITRO和镀锌亚硝基化合物心血管，组合物及使用方法
公开(公告)号：EP1670459A4
公开(公告)日：2009-03-25
申请号：EP04781569
申请日：2004-08-20
申请人： NITROMED INC
发明人： GARVEY DAVID S , LETTS GORDON L , WORCEL MANUEL , GASTON RICKY D
IPC分类号： A61K31/405 , A61K20060101 , A61K31/44 , A61K31/535 , A61P9/02 , C07D209/04 , C07D221/02 , C07D415/00 , C07K5/06
CPC分类号： C07D493/04 , C07D407/04 , C07K5/06026

3. 发明公开

EP2024337A1 SOLID DOSAGE FORMULATIONS OF HYDRALAZINE COMPOUNDS 审中-公开
标题翻译：肼类化合物的固体剂量配方
公开(公告)号：EP2024337A1
公开(公告)日：2009-02-18
申请号：EP07777070.9
申请日：2007-05-16
申请人： Nitromed, Inc.
发明人： LETTS, L., Gordon
IPC分类号： C07D237/26 , A01N25/34
CPC分类号： A61K9/2054 , A61K9/2059 , A61K31/34 , A61K31/502 , A61K45/06 , Y02A50/411 , A61K2300/00
摘要： The invention provides solid dosage formulations, methods of making and using the formulations comprising at least one hydralazine compound or a pharmaceutically acceptable salt thereof, and at least one excipient or carrier, wherein the formulations have less than about 0.001% to about 0.1% of a hydrazone compound based on the total weight of the formulation. The invention also provides solid dosage formulations, methods of making and using the formulations comprising at least one hydralazine compound or a pharmaceutically acceptable salt thereof, and at least one nitric oxide donor compound or a pharmaceutically acceptable salt thereof and at least one excipient or carrier, wherein the formulations have less than about 0.001% to about 0.1% of a hydrazone compound based on the total weight of the formulation.
摘要翻译：本发明提供了固体剂型，制备和使用包含至少一种肼屈嗪化合物或其药学上可接受的盐和至少一种赋形剂或载体的制剂的方法，其中所述制剂具有小于约0.001％至约0.1％的腙化合物，基于配方的总重量。本发明还提供固体剂量制剂，制备和使用包含至少一种肼屈嗪化合物或其药学上可接受的盐和至少一种一氧化氮供体化合物或其药学上可接受的盐以及至少一种赋形剂或载体的制剂的方法，其中所述制剂具有基于所述制剂的总重量小于约0.001％至约0.1％的腙化合物。

4. 发明公开

EP1971340A2 NITRIC OXIDE ENHANCING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE 审中-公开
标题翻译：氮氧化物补强PYRUVATE化合物，组合物及使用方法
公开(公告)号：EP1971340A2
公开(公告)日：2008-09-24
申请号：EP06845699.5
申请日：2006-12-19
申请人： Nitromed, Inc.
发明人： GARVEY, David, S.
IPC分类号： A61K31/537 , A61K31/421
CPC分类号： A61K31/421 , A61K31/537
摘要： The invention provides novel compositions and kits comprising at least one nitric oxide enhancing pyruvate compound, or a pharmaceutically acceptable salt thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (1) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating reperfusion injury following ischemia; and/or (m) preserving tissues, organs, organ parts and/or limbs. The nitric oxide enhancing pyruvate compounds comprise at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group.

5. 发明公开

EP1968584A2 NITRIC OXIDE ENHANCING GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE 审中-公开
标题翻译：氮氧化物增强谷氨酸化合物，组合物及使用方法
公开(公告)号：EP1968584A2
公开(公告)日：2008-09-17
申请号：EP06845698.7
申请日：2006-12-19
申请人： Nitromed, Inc.
发明人： GARVEY, David, S.
IPC分类号： A61K31/4245
CPC分类号： A61K31/4245
摘要： The invention provides novel compositions and kits comprising at least one nitric oxide enhancing glutamic acid compound, or a pharmaceutically acceptable salt thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (1) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating diseases resulting from elevated levels of gamma-glutamyl transpeptidase and (o) targeting the delivery of compounds and nitric oxide to organs, cells or tissues that contain the enzyme gamma-glutamyl transpeptidase. The nitric oxide enhancing glutamic acid compounds comprise at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group.

6. 发明公开

EP1943361A2 THE GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF ALDOSTERONE SYNTHASE PROMOTER POLYMORPHISM 审中-公开
标题翻译：遗传风险评估心力衰竭：影响醛固酮合成酶基因多态性的遗传变异的
公开(公告)号：EP1943361A2
公开(公告)日：2008-07-16
申请号：EP06825494.5
申请日：2006-10-04
申请人： Nitromed, Inc. , University of Pittsburgh of the Commonwealth System of Higher Education
发明人： WORCEL, Manuel , SABOLINSKI, Michael, L. , TAM, Sang, William , McNAMARA, Dennis, M.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , C12Q2600/172
摘要： The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (Ic) decreasing levels of B-type natriuretic protein; (1) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; or (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has a -344 (T/T) polymorphism or a -344 (C/C) polymorphism in an aldosterone synthase CYPl1B2 gene, comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.

7. 发明公开

EP1667643A4 NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE 审中-公开
标题翻译： NITRO和镀锌亚硝基化合物心血管，组合物及使用方法
公开(公告)号：EP1667643A4
公开(公告)日：2008-03-05
申请号：EP04781570
申请日：2004-08-20
申请人： NITROMED INC
发明人： GARVEY DAVID S , LETTS GORDON L , WORCEL MANUEL
IPC分类号： A61K31/4523 , A61K20060101 , A61K31/517 , A61K31/5415 , A61K31/549 , C07D211/00 , C07D285/22 , C07D295/00 , C07D307/00 , C07D417/12 , C07D417/14
CPC分类号： C07D403/10 , C07C205/40 , C07D233/68 , C07D235/18 , C07D257/04 , C07D307/52 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/04 , C07D409/06 , C07D409/14 , C07D413/10 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04

8. 发明公开

EP1883614A2 ORGANIC NITRIC OXIDE ENHANCING SALTS OF NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE 审中-公开
标题翻译：有机氮氧化物增强从非甾体抗炎化合物和组合物及其使用方法盐类
公开(公告)号：EP1883614A2
公开(公告)日：2008-02-06
申请号：EP06770830.5
申请日：2006-05-23
申请人： Nitromed, Inc.
发明人： GARVEY, David, S.
IPC分类号： C07C7/10 , B32B15/00 , A61K31/60
CPC分类号： C07C229/42 , C07C57/58 , C07C59/64 , C07C59/68 , C07C59/84 , C07C59/86 , C07C59/88 , C07C313/36 , C07D209/12 , C07D263/32 , C07D277/24 , C07D279/12 , C07D333/22 , C07D471/04 , C07D498/04
摘要： The invention describes novel organic nitric oxide enhancing salts of nonsteroidal antiinflammatory drugs (NSAIDs) and novel compositions comprising at least one organic nitric oxide enhancing salt of an NSAID, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one organic nitric oxide enhancing salt of an NSAID, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating inflammation, pain and fever; (b) treating gastrointestinal disorders; (c) facilitating wound healing; (d) treating gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; (e) treating inflammatory disease states and/or disorders; (f) treating ophthalmic disorders; (h) treating peripheral vascular diseases; (i) treating diseases resulting from oxidative stress; (j) treating endothelial dysfunctions; and (k) treating diseases caused by endothelial dysfunctions. The organic nitric oxide enhancing compounds that form salts with the NSAIDs are organic nitrates, organic nitrites, nitrosothiols, thionitrites, thionitrates, NONOates, heterocyclic nitric oxide donors and/or nitroxides. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5- imines.

9. 发明授权

EP1284653B1 INFRARED THERMOGRAPHY AND TREATMENT OF SEXUAL DYSFUNCTIONS 有权
标题翻译：红外热像仪和性功能障碍治疗
公开(公告)号：EP1284653B1
公开(公告)日：2007-11-28
申请号：EP01935124.6
申请日：2001-05-08
申请人： Nitromed, Inc.
发明人： MAREK, Przemyslaw, A. , TROCHA, Andrzej, M.
IPC分类号： A61B6/00 , A61K49/00 , A61K31/42 , A61B5/00 , A61P15/00
CPC分类号： A61B5/4368 , A61B5/015 , A61K49/0004 , Y10S514/929
摘要： The present invention describes rapid non-invasive methods for measuring vasodilation or changes in blood flow in a patient following administration of at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent. The method comprises administration of at least one compound to the patient followed by monitoring the temperature change of an area of interest using infrared thermography.

10. 发明公开

EP1852422A3 Nitrosated and nitorsylated alpha-andrenergic receptor antagonist compounds, compositions and their uses 失效
标题翻译：亚硝化和亚硝基化andrenergische的α-受体拮抗剂化合物，它们的组合物，及其用途
公开(公告)号：EP1852422A3
公开(公告)日：2007-11-21
申请号：EP07011814.6
申请日：1997-01-28
申请人： Nitromed, Inc.
发明人： Garvey, David S. , Schroeder, Joseph, D. , Saenz de Tejada, Inigo
IPC分类号： C07D239/95 , C07D233/20 , C07D233/28 , C07D459/00 , C07D311/22 , C07D335/06 , C07D295/08 , A61K31/495 , A61K31/135 , A61K31/435
CPC分类号： C07D459/00 , C07C381/00 , C07D211/62 , C07D233/24 , C07D239/95 , C07D401/04 , C07D405/12 , Y10S514/929
摘要： Disclosed are nitrosated and nitrosylated α-adrenergic receptor antagonists, compositions of an α-adrenergic receptor antagonist (α-antagonist), which can optionally be substituted with at least one NO or NO 2 moiety, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO + ) or nitroxyl (NO - ), or as the neutral species, nitric oxide (NO.); and uses for each of them in treating human impotence or erectile dysfunction.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式